SOLESENCE, INC. SLSN
March 7, 2025, Nanophase Technologies Corporation announced its rebranding as Solésence, Inc. ("Solésence,"
"Company," "we," "our," or "us"), marking a new chapter in its commitment to skin
health innovation and consumer products across beauty, health, and wellness categories. Our corporate website has transitioned
to solesence.com and investor relations information, including historical Nanophase financials and disclosures, is available at
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $62.1M | $52.3M | $37.3M | $37.3M | $29.5M | $17.1M | $12.5M | $14.2M | $12.5M | $10.8M |
| Cost of revenue | $46.0M | $36.2M | $29.5M | $29.0M | $20.8M | $11.1M | $9.9M | $10.9M | $8.6M | $7.5M |
| Gross profit | $16.1M | $16.2M | $7.8M | $8.4M | $8.7M | $6.0M | $2.6M | $3.3M | $3.9M | $3.2M |
| R&D | $4.1M | $3.8M | $3.8M | $3.0M | $2.2M | $1.6M | $1.9M | $2.1M | $1.7M | $1.6M |
| SG&A | $10.4M | $7.2M | $7.5M | $7.6M | $3.9M | $2.9M | $3.5M | $3.3M | $2.9M | $3.0M |
| Total operating expenses | $60.3M | $48.1M | $41.7M | — | — | — | — | — | — | — |
| Operating income | $1.6M | $5.1M | -$3.5M | -$2.3M | $2.6M | $1.5M | -$2.8M | -$2.0M | -$772.0K | -$1.3M |
| Interest expense | — | $670.0K | $838.0K | $382.0K | $1.2M | $496.0K | $210.0K | $58.0K | $34.0K | $15.0K |
| Pre-tax income | $1.9M | $4.5M | -$4.4M | -$2.6M | $2.4M | $989.0K | -$3.0M | -$2.1M | -$789.0K | -$1.3M |
| Income tax | $73.0K | $227.0K | $6.0K | $17.0K | $37.0K | — | — | $0 | $0 | — |
| Net income | $1.8M | $4.2M | -$4.4M | -$2.6M | $2.3M | $989.0K | -$3.0M | -$2.1M | -$789.0K | -$1.3M |
| EPS, basic | 0.03 | 0.07 | -0.09 | -0.05 | 0.05 | 0.03 | -0.08 | — | — | — |
| EPS, diluted | 0.02 | 0.07 | -0.09 | -0.05 | 0.05 | 0.03 | -0.08 | -0.06 | -0.03 | -0.04 |
| Shares, diluted (wtd. avg.) | 72.6M | 65.0M | 49.6M | 49.1M | 47.0M | 38.5M | 36.6M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.3M | $1.4M | $1.7M | $2.2M | $657.0K | $957.0K | $1.2M | $1.3M | $2.0M | $1.8M |
| Receivables | $6.8M | $4.9M | $3.5M | $4.7M | $3.9M | $2.9M | $970.0K | $829.0K | $1.1M | $434.0K |
| Inventory | $18.5M | $20.3M | $10.0M | $8.8M | $6.1M | $4.3M | $2.6M | $2.2M | $1.4M | $772.0K |
| Total current assets | $28.8M | $29.3M | $16.3M | $16.6M | $11.6M | $8.8M | $5.0M | $4.7M | $4.6M | $3.4M |
| Property, plant and equipment | $14.3M | $12.7M | $8.7M | $7.9M | $4.7M | $2.9M | $2.3M | $1.9M | $1.6M | $1.4M |
| Total assets | $50.1M | $50.0M | $32.9M | $33.6M | $28.4M | $13.5M | $9.4M | $6.6M | $6.3M | $4.8M |
| Accounts payable | $4.1M | $9.1M | $6.3M | $6.4M | $3.6M | $2.1M | $1.7M | $1.6M | $1.0M | $669.0K |
| Short-term debt | — | — | — | — | — | $500.0K | $500.0K | — | — | — |
| Total current liabilities | $13.9M | $25.8M | $15.6M | $13.8M | $7.3M | $6.8M | $4.4M | $3.6M | $2.0M | $1.3M |
| Long-term debt | — | — | — | $1.0M | $1.0M | $952.0K | — | — | — | — |
| Retained earnings | -$98.6M | -$100.4M | -$104.7M | -$100.1M | -$97.4M | -$99.8M | -$100.8M | -$97.8M | -$95.7M | -$94.9M |
| Total equity | $17.6M | $14.9M | $1.9M | $5.6M | $7.5M | $2.7M | $1.5M | $1.4M | $3.2M | $2.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.6M | $2.0M | -$2.0M | -$1.6M | $2.3M | -$2.1M | -$2.8M | -$1.3M | -$960.0K | -$241.0K |
| Depreciation and amortisation | $897.0K | $928.0K | $918.0K | $567.0K | $454.0K | $358.0K | $315.0K | $322.0K | $344.0K | $610.0K |
| Stock-based compensation | $575.0K | $725.0K | $773.0K | $625.0K | $160.0K | $195.0K | $242.0K | $204.0K | $183.0K | $207.0K |
| Capital expenditure | — | $4.6M | $1.1M | $2.8M | $1.9M | $878.0K | $740.0K | $160.0K | $209.0K | $128.0K |
| Investing cash flow | -$2.1M | -$4.6M | -$1.1M | -$2.8M | -$1.9M | -$878.0K | -$740.0K | -$160.0K | -$72.0K | -$165.0K |
| Financing cash flow | $10.6M | $2.3M | $2.6M | $6.0M | -$747.0K | $2.7M | $3.4M | $892.0K | $1.2M | $910.0K |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001999371-26-007345.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.8M | $12.5M | $14.2M | $12.5M | $17.1M | $29.5M | $37.3M | $37.3M | $52.3M | $62.1M |
| Gross profit | $3.2M | $3.9M | $3.3M | $2.6M | $6.0M | $8.7M | $8.4M | $7.8M | $16.2M | $16.1M |
| Net income | -$1.3M | -$789.0K | -$2.1M | -$3.0M | $989.0K | $2.3M | -$2.6M | -$4.4M | $4.2M | $1.8M |
Recent filings and events
- Accounts can no longer be relied on The company is telling investors that figures it has already published are wrong. Rare, and about as direct as a filing gets. Item 4.02
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Officer or director change Item 5.02
- Material agreement signed Item 1.01
- Officer or director change Item 5.02
- Results announced Item 2.02
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2844
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| CL | COLGATE PALMOLIVE CO | $74.97B | 35.8x | 1.4% |
| EL | ESTEE LAUDER COMPANIES INC | $39.37B | 217.3x | 5.0% |
| KVUE | Kenvue Inc. | $37.59B | 25.8x | -2.1% |
| ELF | e.l.f. Beauty, Inc. | $6.74B | 259.6x | 24.6% |
| IPAR | INTERPARFUMS INC | $3.69B | 22.0x | 2.5% |
| COTY | COTY INC. | $2.84B | — | -1.5% |
| EPC | EDGEWELL PERSONAL CARE Co | $1.29B | 52.9x | -1.3% |
| WALD | Waldencast plc | $100.3M | — | -0.7% |